Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250024/S005

Trilogy Transcatheter Heart Valve System

JenaValve Technology, Inc. · Decision date Oct 13, 2026

MEDTECHLEDGER EXPLANATIONP250024/S005

What did the FDA decide?

The FDA record for P250024/S005, dated 2026-10-13, is a 30-Day Notice under the Trilogy Transcatheter Heart Valve System PMA, filed by JenaValve Technology, Inc. The supplement reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the stated change is "an additional abattoir for sourcing pericardium tissue." The device category is a percutaneously delivered aortic valve prosthesis (product code NPT).

Because the record names P250024, this submission modifies the existing PMA rather than granting approval of the whole system; the decision is logged as OK30, and the notice concerns a supplier arrangement for pericardium tissue sourcing. The supplied fields do not identify the abattoir, its location, tissue acceptance criteria, or any verification data tied to the added source. The stated purpose of the notice is not evidence of safety or clinical effectiveness.

FDA approval order statement

an additional abattoir for sourcing pericardium tissue
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 13, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250024/S005
Regulatory pathway
PMA supplement
Product code
NPT
Decision code
OK30
Decision date
Oct 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Aortic valve, prosthesis, percutaneously delivered.

Product code
NPT
FDA device class
3

For the original device and its historical approval scope, see PMA P250024. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250024 · Original PMA

    Trilogy Transcatheter Heart Valve System

  2. P250024/S005 received

    Application receipt date recorded by FDA.

  3. P250024/S006 · Related supplement

    Trilogy Transcatheter Heart Valve System

  4. P250024/S005 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P250024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250024

Product / regulatory recordCompanyPathwayDecision dateSource
JenaValve Technology, Inc.PMA approvalMar 17, 2026FDA
JenaValve Technology, Inc.PMA supplementOct 7, 2026FDA

Explore the linked device profile

Other records with product code NPT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

JenaValve Technology, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4 Cromwell, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records